Eton Pharmaceuticals, Inc. (ETON)

Every figure this model derived for ETON, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 403,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 26,845,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 68,599,000 AssetsCurrent 2026-06-30
current liabilities 45,124,000 LiabilitiesCurrent 2026-06-30
equity 46,585,000 StockholdersEquity 2026-06-30
interest expense 4,170,000 InterestPaidNet 2026-06-30
ocf 10,524,000 NetCashProvidedByUsedInOperatingActivities 2025-12-31
revenue 105,595,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 5,202,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ETON on one particular measure came for.

RatioValue
cash operating margin24.67
current ratio1.52
current ratio reported1.52
dilution pct3.91
fcf margin9.58
growth cv1.99
interest cover3.91
net debt ebitda0.05
operating margin15.44
owner earnings margin4.66
revenue growth81.49
revenue growth per share74.66
roic27.06
rule of 4096.94
sbc pct revenue4.93

What to be careful about

What this model itself distrusts about ETON's figures. Written by the derivation as it ran, not added afterwards.